What Researchers Did
Researchers investigated the effects of memantine, an NMDA receptor antagonist, combined with hyperbaric oxygen therapy on hippocampal dysfunction and white matter injury in patients receiving cranial radiation for central nervous system malignancies.
What They Found
Treatment with memantine alone reversed impairment in hippocampal pattern separation networks, as detected by functional magnetic resonance imaging. The combination of hyperbaric preconditioning and memantine mostly reversed white matter injury and facilitated the restoration of hippocampal function, leading to improved higher cognitive function in patients.
What This Means for Canadian Patients
This therapeutic approach could potentially mitigate the cognitive side effects of cranial radiation, improving the quality of life for Canadian patients undergoing brain cancer treatment. It offers a promising strategy to preserve vital brain functions during necessary cancer therapies.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
The abstract does not detail the study's sample size or the long-term efficacy of the intervention.